Sign up USA
Proactive Investors - Run By Investors For Investors

Catabasis surges after successful mid-stage trial of its DMD treatment

Catabasis’ edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed
boy walking on beach
DMD almost exclusively affects young boys and there is current no known cure

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) surged on Tuesday after the biopharma reported positive results from a mid-stage study of its Duchenne muscular dystrophy treatment.

In the trial, the company’s edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed.

Consistent improvements in all assessments of muscle function were observed after more than a year of treatment compared to the rate of change in the pre-specified control period.

DMD is a rare muscle-wasting disease that almost exclusively affects only young boys, for which there is currently no known cure.

Importantly, Catabasis is looking to treat all DMD sufferers with edasalonexent rather than just a subset of patients.

A pivotal phase III trial is scheduled to get underway in the first half of this year, with top-line data expected in 2020.

“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said chief executive Jill Milne.

“Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease.”

Catabasis shares soared by a quarter to US$1.57 on Tuesday.

View full CATB profile View Profile

Catabasis Pharma Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use